Impact médico-économique des thérapies ciblées et des traitements immuno-oncologiques dans la prise en charge des cancers broncho-pulmonaires avancés ou métastatiques en France

Abstract : Lung cancer is the fourth most common cancer with the highest mortality rate in France. The French healthcare system offers a mainly public funding model, and medical costs generated by this pathology are fully covered by Health Insurance. The arrival of immunotherapy has modified the management of advanced or metastatic non-small cell lung cancer. This analysis aims to assess whether therapeutic innovations in lung cancer have a budgetary impact on the health system. For that purpose, the 2017 actual medical costs of this pathology were studied, as well as the coming years costs within a specific forecast analysis to 2022. A model integrating medical parameters, changes in treatment, care and testing was built and studied. This study shows a budgetary impact of therapeutic innovations on the health system. The average one-year cost of treatment for a patient with advanced or metastatic non-small cell lung cancer was approximately € 53,000 in 2017 and would approach € 76,000 by 2022. This trend is consistent with the assumption of the increasingly important use of targeted therapies and immunotherapies. The associated costs for palliative care and acquisition costs of therapies are the most significant expenses in the management of NSCLC IIIB / IV.
Document type :
Master Thesis
Complete list of metadatas

Cited literature [85 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-01988084
Contributor : Jean-Hugues Morneau <>
Submitted on : Monday, January 21, 2019 - 3:11:31 PM
Last modification on : Wednesday, February 27, 2019 - 10:55:26 PM

File

2018GREA7073_plichta_agathe(1)...
Files produced by the author(s)

Identifiers

  • HAL Id : dumas-01988084, version 1

Citation

Agathe Plichta. Impact médico-économique des thérapies ciblées et des traitements immuno-oncologiques dans la prise en charge des cancers broncho-pulmonaires avancés ou métastatiques en France. Sciences pharmaceutiques. 2018. ⟨dumas-01988084⟩

Share

Metrics

Record views

60

Files downloads

152